Biophytis is a biotechnology business based in the US. Biophytis shares (BPTS) are listed on the NASDAQ and all prices are listed in US Dollars. Biophytis employs 24 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $0.43 |
|---|---|
| 52-week range | $0.35 - $3.36 |
| 50-day moving average | $0.48 |
| 200-day moving average | $0.68 |
| Wall St. target price | $15.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.82 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.429 from 2023-03-24
| 1 week (2023-03-21) | 4.38% |
|---|---|
| 1 month (2023-02-28) | 3.13% |
| 3 months (2022-12-28) | 8.61% |
| 6 months (2022-09-28) | -32.44% |
| 1 year (2022-03-28) | -84.23% |
|---|---|
| 2 years (2021-03-26) | -96.65% |
| 3 years (2020-03-24) | N/A |
| 5 years (2018-03-24) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -50.67% |
| Return on equity TTM | -680.78% |
| Profit margin | 0% |
| Book value | $0.20 |
| Market capitalisation | $10.4 million |
TTM: trailing 12 months
We're not expecting Biophytis to pay a dividend over the next 12 months.
You may also wish to consider:
Biophytis's shares were split on a 1:10 basis on 30 March 2023. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Biophytis shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Biophytis shares which in turn could have impacted Biophytis's share price.
Over the last 12 months, Biophytis's shares have ranged in value from as little as $0.35 up to $3.36. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biophytis's is 1.1834. This would suggest that Biophytis's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put Biophytis's beta into context you can compare it against those of similar companies.
Biophytis S. A. , a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.